Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 13/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3332045 | 0.94 | P2RY12 (0.46) | P2RY12ALDH1A1CYP1A2POLBCYP2C9 | |
| SCHEMBL3332041 | 0.94 | P2RY12 (0.46) | P2RY12ALDH1A1CYP1A2POLBCYP2C9 | |
| Trifluoroacetic Acid SCHEMBL955821 | 0.92 | ALDH1A1 (0.49) | P2RY12ALDH1A1CYP1A2POLBCYP2C9 | |
| SCHEMBL951464 | 0.88 | DPP7 (0.46) | P2RY12ALDH1A1CYP1A2POLBCYP2C9 | |
| SCHEMBL951463 | 0.88 | DPP7 (0.46) | P2RY12ALDH1A1CYP1A2POLBCYP2C9 | |
| SCHEMBL3332323 | 0.86 | TSHR (0.55) | ALDH1A1CYP1A2POLBCYP2C9TSHR | |
| SCHEMBL3332321 | 0.86 | TSHR (0.55) | ALDH1A1CYP1A2POLBCYP2C9TSHR | |
| SCHEMBL524011 | 0.83 | HDAC8 (0.52) | P2RY12ALDH1A1CYP1A2POLBCYP2C9 | |
| SCHEMBL524012 | 0.83 | HDAC8 (0.52) | P2RY12ALDH1A1CYP1A2POLBCYP2C9 | |
| SCHEMBL954599 | 0.81 | TSHR (0.52) | ALDH1A1CYP1A2POLBCYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | P2RY12 1/4885ALDH1A1 2297/4885CYP1A2 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.